Loading
A phase 1/2 trial of Entrectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options is a phase 1/2 interventional study registered as NCT02650401 by Hoffmann-La Roche, with 69 participants enrolled, started 2016-05-03 and due to reach its primary completion in 2026-06-30. Interventions recorded: Entrectinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Entrectinib, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/